<DOC>
	<DOCNO>NCT01761773</DOCNO>
	<brief_summary>The main objective trial compare pharmacokinetics 60 mg dose cabozantinib adult subject impair renal function compare healthy adult subject . Another objective ass safety tolerability cabozantinib adult subject .</brief_summary>
	<brief_title>A Single-Dose Study Assess Pharmacokinetics Cabozantinib ( XL184 ) Capsules Subjects With Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Body weight must ≥ 50 kg &lt; 130 kg BMI ≤ 38.0 ( kg/m2 ) . Must use acceptable form birth control course study 3 month follow single dose study drug . Female subject childbearing potential must negative pregnancy test screening checkin . Negative test HIV ; hepatitis A , B , C. Must adequate vital sign read screen checkin . Must able comply dietary fluid restriction require study . History medical surgical condition would interfere GI absorption , distribution , metabolism , excretion study drug . Recent clinical evidence pancreatic injury . Recent use drug know significantly inhibit induce P450 CYP3A4 enzymes . Previous diagnosis malignancy . Unwilling forgo use overthecounter nonprescription preparation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>